Investors

Founding-stage capital. Patient horizons. Public accountability from day one.

OUR APPROACH

Disciplined science-led brands, compounded over decades.

Omsita is being capitalized to support a long-horizon thesis: that disciplined science-led brands can compound trust and value over decades, not quarters. We are seeking founding partners aligned with that timeline — and an operating philosophy that puts product integrity, transparent governance, and patient research ahead of growth at any cost.

WHAT WE WILL PUBLISH

Transparency on a public timeline.

  • Q4 2026 — founding governance charter and initial board composition
  • 2027 — first annual financial report
  • 2028 — first product-cycle financial disclosures (Triberine)
  • 2029 — first independent ESG audit results
  • 2030 — comprehensive progress report against founding 2030 commitments
  • Ongoing — material disclosures published in plain English as events warrant
GET IN TOUCH

Founding investor relations.

At this stage, we are speaking only with accredited investors aligned with our long-horizon thesis. Please write to investors@omsita.com with a brief introduction and the kind of partnership you are exploring. We will respond within five business days.